Article

A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenol

2022-09-26

Abstract excerpt

Background: TMS-007, an SMTP family member, modulates plasminogen conformation and enhances plasminogen-fibrin binding, leading to promotion of endogenous fibrinolysis. Its anti-inflammatory action mediated by soluble epoxide hydrolase inhibition contributes to the efficacy. Evidence suggests that TMS-007 can effectively treat experimental thrombotic and embolic strokes with a wide time window while reducing hemor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 56160e82-08e5-5d62-93cc-527a97ec09a7
DOI: 10.22541/au.166419010.08485488/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenolDOI 10.22541/au.166419010.08485488/v1Read

Off Label Use of Tenecteplase in the Management of High-Risk Pulmonary EmbolismSemantic proximity Read

Targeting Thymidine Phosphorylase with Tipiracil Hydrochloride is a Safe and Effective Antithrombotic TherapySemantic proximity Read

Blood-brain barrier permeability and tPA-mediated neurotoxicity.Semantic proximity Read

Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator.Semantic proximity Read

Plasminogen Tochigi mice exhibit phenotypes similar to wild-type mice under experimental thrombotic conditions.Semantic proximity Read

Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke.Semantic proximity Read

S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin.Semantic proximity Read

First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy VolunteersSemantic proximity Read

A First-in-human phase I study of an innovative selective inhibitor targeting coagulation factor XI/XIa in healthy volunteersSemantic proximity Read

Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss.Semantic proximity Read

Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli.Semantic proximity Read

Studies on the regulation of tissue plasminogen activator activity by physiological templatesSemantic proximity Read